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LEADING ARTICLE 
Regulatory Requirements for Medical Devices in the European 
Union 
B. C. Eikelboom and P. Duijst 
Introduction 
It is well known in the medical community that the 
introduction of a new drug is a difficult, time- 
consuming and costly process. In the past it was 
relatively easy to introduce new medical devices, such 
as vascular grafts, because it depended mainly on 
local arrangements between the manufacturers and 
surgeons. At that time Europe had no equivalent to the 
FDA in the United States, and it was not surprising, 
therefore, that many companies tried to avoid the 
hurdles of the FDA by going to Europe for the clinical 
evaluation of new products. Fortunatel~ most com- 
panies behaved in a responsible manner, but some of 
them were less scrupulous. The situation could be 
characterised by the following, hopefully theoretical, 
discussion amongst company officials: 'What experi- 
ments shall we do next: pigs, goats or Europeans?' 
Thankfully, this is no longer the case, as Europe now 
has its own set of regulatory requirements through the 
Medical Devices Directive (MDD) of the European 
Union. 
After a transition period that began on 1 January 
1995, this European law will be mandatory for all EU 
member states as of 14 June 1998. It serves two 
purposes--first, to provide protection for both 
patients and users of devices, second, to lift trade 
barriers. Vascular grafts and stents fall within the 
scope of the MDD, which makes it imperative for the 
vascular surgical community to have a clear under- 
standing of its implications. Once the MDD has 
become mandator~ the European Union will allow 
only clinical application of medical devices which 
have obtained the so-called CE Mark. This applies not 
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only to new devices, but also to those that are 
currently in use. Therefore, the CE mark should be 
regarded as a symbol of quality, the European equiva- 
lent of the FDA approval. Should a manufacturer wish 
to affix the CE Mark to a device, he must be able to 
demonstrate hat the device conforms with the Essen- 
tial Requirements a outlined in the MDD. When all of 
the criteria of conformity with the MDD requirements 
are met, it means that the device will not jeopardise 
the individual patient's clinical condition and that it 
wil operate according to the claims of the manu- 
facturer. In other words, the device will have been 
shown to meet a specific level of safety and 
performance. 
The CE Mark is obtained through Notified Bodies, 
such as KEMA in the Netherlands, TUV in Germany 
and BSI in the U.K. These are test-houses--technical 
institutions--dealing with quality assurance audits 
and the assessment of preclinical and clinical data. 
When a company wishes to CE Mark one of its 
products it will choose a Notified Body in any of the 
European Union countries. Once the CE Mark has 
been obtained, it is valid for all other European Union 
countries. 
There are two crucial elements in the CE Marking 
process and these are the certification of the manu- 
facturer's Quality Assurance System and supporting 
test data on the device for which the CE Mark is 
required. In this way, not only is the device tested, but 
also the complete manufacturing process. The manu- 
facturer's quality assurance is accredited according to 
the Standard EN29000, which is the European equiva- 
lent of the International Standard ISO9000. These 
standards require specific details covering the entire 
process from the design phase to the actual stage of 
production, sterilisation, packaging, labelling etc.. Test 
data comprise biocompatibility data, preclinical tests 
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such as in vitro stress tests, animal experiments, and, 
most importantly, clinical evaluation data to demon- 
strate sufficient safety for the patient. 
Clinicians must, therefore, be aware of the guide- 
lines which have been laid down for the clinical 
evaluation of devices. The MDD refers to the Declara- 
tion of Helsinki in the relevant section dealing with 
clinical investigation (Annex X) and it is in accordance 
with this Declaration that all clinical evaluations 
should be carried out. This Annex X is supported by a 
set of guidelines laid down in the European Standard 
EN540, entitled 'Clinical Investigation of Medical 
Devices for Human Subjects'. This document 
describes in detail the methodology to follow, the role 
of the various parties involved and the manner in 
which to present the results to the Notified Body. The 
company (sponsor) has to compile a clinical investiga- 
tion dossier which contains a literature surve)~ a 
description of the device, a summary of the preclinical 
studies and previous clinical investigations. It must 
also contain a clinical investigation plan which 
includes the justification for the study and the names 
of the investigators. The investigators have the right to 
demand relevant preclinical investigation informa- 
tion. This information must be kept confidential. The 
investigator signs the protocol and submits it to an 
appropriate Ethics Committee. Once the approval has 
been granted, the company notifies the Competent 
Authorit)~ usually the Ministry of Health (Medical 
Devices Agency in the U.K.) The Competent Authority 
reviews the study protocol within 60 days along with 
the Ethics Committee approval and any additional 
preclinical/in vitro data. After this period, the study 
may commence unless the Competent Authority's 
opinion is unfavourable. The investigator must inform 
the patient adequatel)~ both in oral and written form, 
about the study in which he is being asked to 
participate. This information must include the aims of 
the stud)~ expected benefits to the patient, potential 
risks and inconveniences, explanations of alternative 
treatments, consequences of withdrawal from the 
study and procedures for compensation a d treatment 
in case of injury/disability. Patients remain free to 
refuse to participate or to withdraw from the study at 
any moment without prejudice. The identity of the 
patient is unknown to the sponsor and the data 
collected may be made available to third parties. After 
having been informed fully, the patient may agree to 
participate in the study and sign the consent form. The 
investigator must report serious adverse events and 
all adverse device effects to the sponsor, who dis- 
cusses and investigates the event with the clinician. 
The outcome is reported to the Competent 
Authority. 
When all the data has been collected, a final report 
is written which takes into account all data from all of 
the participating centres. The data is analysed and an 
initial evaluation provided. The final report is signed 
by all of the clinical investigators and the study 
sponsor. The clinical records and investigation data 
must be kept by the investigator for an appropriate 
length of time, usually 10 years. The final report will 
be used by the sponsoring company in his application 
for the CE Mark and may then be used by the 
investigators for publications and presentations. 
It is clear that this process requires close co- 
operation between clinicians and medical device 
companies. Clinical involvement in properly con- 
trolled studies is of the utmost importance to obtain 
the CE Mark and from 1998 onwards vascular sur- 
geons must only use implants which carry the CE 
mark. Some surgeons will regard this process as 
compromising their clinical judgment in providing the 
best treatment to their patients. Some of the com- 
panies will regard this process as time-consuming and 
expensive. All of these arguments are understandable, 
but proper protection for patients and the users of 
medical devices must be of over-riding and para- 
mount importance. We believe strongly that the 
European regulatory requirements provide new 
opportunities for improved patient care in a responsi- 
ble way through close interaction between clinicians, 
industry and the various authorities. 
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